Consolidative thoracic radiotherapy improves the prognosis of extensive stage small-cell lung cancer patients in the chemoimmunotherapy era: a multicenter retrospective analysis.

Authors

Nan Yao, Shuai Li, Lingling Hu, Yixian Pei, Zhaohui Qin, Na Li, Shaodong Tong, Nan Zhang, Yuanhu Yao

Published in

Annals of medicine. Volume 57. Issue 1. Pages 2542434. Epub Aug 04, 2025.

Abstract

For extensive-stage small cell lung cancer (ES-SCLC) with intrathoracic residuals after chemotherapy, the landmark CREST trial demonstrated the benefit of consolidative thoracic radiotherapy (cTRT). Yet the efficacy and safety of cTRT after chemoimmunotherapy for ES-SCLC remain largely unknown. This study aimed to assess the role of cTRT following chemoimmunotherapy in patients with ES-SCLC.
A retrospective analysis of ES-SCLC patients without disease progression after first-line chemoimmunotherapy was conducted between March 2019 and November 2021. Based on whether cTRT or not, patients were allocated to cTRT group or non-cTRT group. We evaluated efficacy by using the median overall survival (mOS) and progression-free survival (mPFS) times, and safety by measuring the incidence of adverse events.
During this study, 72 patients with ES-SCLC were enrolled, with a median follow-up of 34.66 months. Twenty-nine patients received cTRT and 43 patients did not receive cTRT. Among the cTRT group and the non-cTRT group, the mPFS was 11.50 and 8.02 months, respectively, with a HR of 0.60 (95% CI 0.36-0.99, p = 0.043). The mOS in the cTRT group was also significantly longer than that in the non-cTRT group (28.68 months vs. 16.30 months, HR = 0.56, 95% CI 0.32-0.96, p = 0.033). Based on multivariate analysis, cTRT and cycles of immunotherapy ≥ 6 were independent factors affecting survival. There were no treatment-related deaths and most adverse events were grade 1-2.
This study suggests that the addition of cTRT to first-line chemo-immunotherapy significantly improves survival in ES-SCLC with well-tolerated toxicity.

PMID:
40755353
Bibliographic data and abstract were imported from PubMed on 04 Aug 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.